CL2019002893A1 - Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos. - Google Patents

Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos.

Info

Publication number
CL2019002893A1
CL2019002893A1 CL2019002893A CL2019002893A CL2019002893A1 CL 2019002893 A1 CL2019002893 A1 CL 2019002893A1 CL 2019002893 A CL2019002893 A CL 2019002893A CL 2019002893 A CL2019002893 A CL 2019002893A CL 2019002893 A1 CL2019002893 A1 CL 2019002893A1
Authority
CL
Chile
Prior art keywords
receptor agonists
nuclear receptor
isoxazole derivatives
isoxazole
derivatives
Prior art date
Application number
CL2019002893A
Other languages
English (en)
Inventor
Jae-Hoon Kang
Hong-Sub Lee
Yoon-Suk Lee
Jin-Ah Jeong
Sung-Wook Kwon
Jeong-Guen Kim
Kyung-Sun Kim
Dong-Keun Song
Sun-Young Park
Kyeo-Jin Kim
Ji-Hye Choi
Hey-Min Hwang
Original Assignee
Il Dong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Dong Pharma filed Critical Il Dong Pharma
Publication of CL2019002893A1 publication Critical patent/CL2019002893A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE ISOXAZOL, INCLUYENDO COMPOSICIONES FARMACÉUTICAS Y A LA PREPARACIÓN DE DERIVADOS DE ISOXAZOL. Y MÁS ESPECIALMENTE, LA PRESENTE INVENCIÓN PROPORCIONA UNA COMPOSICIÓN FARMACÉUTICA DE DERIVADOS DE ISOXAZOL PARA LA ACTIVACIÓN DE UN RECEPTOR FARNESOIDE X (FXR, NR1H4).
CL2019002893A 2017-04-12 2019-10-10 Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos. CL2019002893A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170047393 2017-04-12
KR1020180042545A KR102168543B1 (ko) 2017-04-12 2018-04-12 핵 수용체의 효능제인 아이속사졸 유도체 및 이의 용도

Publications (1)

Publication Number Publication Date
CL2019002893A1 true CL2019002893A1 (es) 2020-03-06

Family

ID=64102389

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002893A CL2019002893A1 (es) 2017-04-12 2019-10-10 Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos.

Country Status (26)

Country Link
US (2) US10988449B2 (es)
EP (1) EP3612520B1 (es)
JP (1) JP6886074B2 (es)
KR (2) KR102168543B1 (es)
CN (1) CN110678450B (es)
AU (1) AU2018252880B2 (es)
CA (1) CA3059869C (es)
CL (1) CL2019002893A1 (es)
CY (1) CY1124936T1 (es)
DK (1) DK3612520T3 (es)
ES (1) ES2904294T3 (es)
HR (1) HRP20220026T1 (es)
HU (1) HUE057429T2 (es)
IL (1) IL269896B (es)
LT (1) LT3612520T (es)
MX (2) MX2019012167A (es)
NZ (1) NZ758117A (es)
PE (1) PE20191792A1 (es)
PH (1) PH12019502326A1 (es)
PL (1) PL3612520T3 (es)
PT (1) PT3612520T (es)
RS (1) RS62711B1 (es)
RU (1) RU2741306C1 (es)
SG (1) SG11201908235RA (es)
SI (1) SI3612520T1 (es)
ZA (1) ZA201906541B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2023090859A1 (ko) * 2021-11-17 2023-05-25 일동제약(주) 아이속사졸 유도체의 제조 방법 및 그의 신규한 중간체
WO2024005586A1 (ko) * 2022-06-30 2024-01-04 일동제약(주) 아이속사졸 유도체 또는 이의 염의 신규한 결정형
WO2024005587A1 (ko) * 2022-06-30 2024-01-04 일동제약(주) 아이속사졸 유도체 또는 이의 염의 신규한 용도
US11905260B1 (en) 2023-10-13 2024-02-20 King Faisal University N′-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound
US11970467B1 (en) 2023-10-13 2024-04-30 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940958D1 (de) 1998-12-23 2009-07-16 Glaxo Group Ltd Bestimmungsmethode fur liganden der nuklearen rezeptoren
DE10130020A1 (de) * 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
JP2006515838A (ja) 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
RU2008128823A (ru) 2005-12-15 2010-01-20 Экселиксис, Инк. (Us) Производные азепиноиндола в качестве фармацевтических средств
WO2007076260A2 (en) 2005-12-19 2007-07-05 Smithkline Beecham Corporation Farnesoid x receptor agonists
WO2007092751A2 (en) 2006-02-03 2007-08-16 Eli Lilly And Company Compounds and methods for modulating fx-receptors
JP2007230909A (ja) 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
CA2651373A1 (en) * 2006-05-24 2007-12-06 Eli Lilly And Company Compounds and methods for modulating fxr
EP2029547B1 (en) 2006-05-24 2010-04-28 Eli Lilly And Company Fxr agonists
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
JP2010529996A (ja) 2007-06-13 2010-09-02 グラクソスミスクライン エルエルシー ファルネソイドｘ受容体アゴニスト
MX2009013946A (es) 2007-07-02 2010-03-10 Glaxosmithkline Llc Agonistas del receptor de farnesoide x.
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
EP2289883A1 (en) * 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
CN107106555A (zh) 2014-12-18 2017-08-29 诺华股份有限公司 氮杂双环辛烷衍生物作为fxr激动剂在治疗肝脏和胃肠疾病中的应用

Also Published As

Publication number Publication date
KR20180115233A (ko) 2018-10-22
SI3612520T1 (sl) 2022-01-31
US11912674B2 (en) 2024-02-27
EP3612520A4 (en) 2020-12-09
BR112019021320A2 (pt) 2020-05-19
IL269896B (en) 2022-07-01
NZ758117A (en) 2022-01-28
CY1124936T1 (el) 2023-01-05
PE20191792A1 (es) 2019-12-24
EP3612520A1 (en) 2020-02-26
MX2022006823A (es) 2022-07-11
IL269896A (es) 2019-11-28
US20210188790A1 (en) 2021-06-24
DK3612520T3 (da) 2021-12-06
KR20200123051A (ko) 2020-10-28
HRP20220026T1 (hr) 2022-04-01
RU2741306C1 (ru) 2021-01-25
PL3612520T3 (pl) 2022-03-21
KR102168543B1 (ko) 2020-10-21
KR102301152B1 (ko) 2021-09-14
JP6886074B2 (ja) 2021-06-16
MX2019012167A (es) 2022-08-12
JP2020516697A (ja) 2020-06-11
LT3612520T (lt) 2022-02-10
AU2018252880A1 (en) 2019-10-17
PH12019502326A1 (en) 2020-09-21
SG11201908235RA (en) 2019-10-30
US10988449B2 (en) 2021-04-27
ZA201906541B (en) 2023-05-31
CA3059869C (en) 2022-01-04
CN110678450A (zh) 2020-01-10
US20200115349A1 (en) 2020-04-16
CA3059869A1 (en) 2018-10-18
ES2904294T3 (es) 2022-04-04
RS62711B1 (sr) 2022-01-31
EP3612520B1 (en) 2021-11-10
PT3612520T (pt) 2022-01-06
CN110678450B (zh) 2023-06-20
HUE057429T2 (hu) 2022-05-28
AU2018252880B2 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
CL2019002893A1 (es) Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos.
SV2018005799A (es) Compuestos moduladores de fxr (nr1h4)
CL2017001675A1 (es) Derivados de quinazolina utilizados para tratar el vih
UY36452A (es) Novedosos compuestos moduladores de fxr (nr1h4)
CL2023001911A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
UY36445A (es) Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi)
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
NI201700078A (es) Pirazolpiridinaminas
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
CR20180256A (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico
UY36195A (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
CR20160373A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
CR20160585A (es) Polipéptidos receptores formulados y métodos relacionados
UY35956A (es) Formulación de atazanavir y cobicistat para el tratamiento del vih